Marlow, Can't seem to find any other company in BOCX past, it has obtained patents in China, had a 2004 test run in Japan with positive results (in the 80's) by no follow up. Possibly you are thinking of BIPH which was mentioned on the same thread down in the .16 area as was BOCX.
Both eventually flew but BOCX got the SEC's attention thanks to their claim that a simple blood test could replace all the expensive mumbo-jumbo in cancer screening. It could become a regular part of standard blood tests. The only critics I can find complain it won't tell you where the cancer is, but I would think the early notice that something is "goin on" somewhere inside will prove an invaluable early detection notice that more tests are needed.
I believe Abbott's (with sales in the billion$) interest is an indication RECAF is real and the market could be huge in TIME.
I got this letter from Abbott on April 11,2005:
Hello John,
Thank you for your interest in the BioCurex agreement. Products using
RECAF are in the development stage right now. First, automated assays
need to be developed, validated and cleared by the FDA before RECAF will
be available. Additional studies will need to be published using these
assays to validate the medical utility of the marker independent of the
original publications.
We're glad that you're interested in this emerging biomarker. Abbott
will continue to provide ongoing updates as development efforts progress
on this biomarker through scientific poster sessions or papers at future
industry meetings.
Sincerely,
Abbott
John G. Mueller/ aka SMOKE
Market Data 
Markets 
AI
